<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048135</url>
  </required_header>
  <id_info>
    <org_study_id>BIO89-100-002</org_study_id>
    <nct_id>NCT04048135</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of BIO89-100 in Subjects With Biopsy Confirmed NASH or NAFLD and at High Risk of NASH</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100 Administered Subcutaneously in Subjects With Nonalcoholic Steatohepatitis (NASH) or With Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>89bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ProSciento</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>89bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1: This is a multi-center evaluation of BIO89-100 (administered weekly or every other&#xD;
      week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in&#xD;
      subjects with NASH and NAFLD at high risk of NASH, including a pre-defined number of subjects&#xD;
      with biopsy confirmed NASH and fibrosis stages F1-F3 to be enrolled&#xD;
&#xD;
      Part 2: This is a multi-center, open label evaluation of BIO89-100 at 27 mg administered&#xD;
      weekly for 20 weeks in subjects with biopsy-poven NASH (NAS ≥4, fibrosis stage F2 or F3)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">August 28, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Cohorts 1-6 is blinded, Cohort 7 is open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Part 1-16 weeks, Part 2-23 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who discontinued due to AEs and due to related AEs</measure>
    <time_frame>Part 1 only-16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the BIO89-100 Pharmacokinetics (PK) by Peak Plasma Concentration</measure>
    <time_frame>Part 1 only-13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the BIO89-100 PK by Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Part 1 only-13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the BIO89-100 PK by Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Part 1 only-13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the BIO89-100 PK by the terminal elimination half-life (t1/2)</measure>
    <time_frame>Part 1 only-13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize effect of BIO89-100 on liver histology by Improvement in NAS score</measure>
    <time_frame>Part 2 only-20 weeks</time_frame>
    <description>At least a 2-point improvement in NAFLD Activity Score (NAS) with at least a 1 point improvement in ballooning or lobular inflammation, and no worsening of fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>Part 1-13 weeks, Part 2-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in triglycerides</measure>
    <time_frame>Part 1-13 weeks, Part 2-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>Part 1-13 weeks, Part 2-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in Alanine Transaminase (ALT)</measure>
    <time_frame>Part 1-13 weeks, Part 2-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in N-terminal type III collagen propeptide (Pro-C3)</measure>
    <time_frame>Part 1-13 weeks, Part 2-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the incidence and characteristics of anti drug antibodies (ADA) developed against BIO89-100 after dosing</measure>
    <time_frame>Part 1-16 week, Part 2-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize effect of BIO89-100 on liver histology by improvement of fibrosis</measure>
    <time_frame>Part 2 only-20 weeks</time_frame>
    <description>Improvement of fibrosis ≥1 stage without worsening of NASH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize effect of BIO89-100 on liver histology by NASH resolution</measure>
    <time_frame>Part 2 only-20 weeks</time_frame>
    <description>NASH resolution without worsening of fibrosis</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>NASH</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIO89-100</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Dose 4 Open Label</arm_group_label>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_label>Dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be 21 to 75 years of age inclusive, at the time of signing the informed&#xD;
             consent form (ICF).&#xD;
&#xD;
          -  Evidence of steatosis by Fibroscan and MRI-PDFF&#xD;
&#xD;
          -  NASH or NAFLD at high risk for NASH as reflected by AT LEAST ONE of the following:&#xD;
&#xD;
          -  Diagnosis of NASH with fibrosis (stages F1, F2 or F3), without cirrhosis, by&#xD;
             percutaneous liver biopsy within 24 months prior to screening&#xD;
&#xD;
          -  Central obesity WITH T2DM&#xD;
&#xD;
          -  Central obesity WITH either increased ALT and/or Fibroscan VCTE score ≥7 KPa.&#xD;
&#xD;
          -  Part 2 only: Biopsy-proven NASH in a liver biopsy obtained within 24 weeks of baseline&#xD;
             with fibrosis stage F2 or F3 and NAS ≥4, with a score of at least 1 in each of&#xD;
             steatosis, ballooning degeneration, and lobular inflammation. A small number of high&#xD;
             risk F1 allowed.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant disorder or a history of any illness that, in the opinion of&#xD;
             the Investigator, might confound the results of the study, or pose additional risk to&#xD;
             the subject by participation in the study.&#xD;
&#xD;
          -  History of type 1 diabetes.&#xD;
&#xD;
          -  Weight loss of more than 5% within 3 months prior to Day -1 or more than 10% within 6&#xD;
             months prior to Day -1 or planning to try to lose weight during conduct of study.&#xD;
&#xD;
          -  History of a liver disorder other than NASH or clinical suspicion of a liver disorder&#xD;
             other than NASH&#xD;
&#xD;
          -  History of cirrhosis or evidence of cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlton, MD</last_name>
    <role>Study Director</role>
    <affiliation>89bio, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Madison</city>
        <state>Alabama</state>
        <zip>35758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 4, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH, NAFLD</keyword>
  <keyword>Liver diseases</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Metabolic diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

